AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024.